Current treatment guidelines in the United States suggest a thiazide diuretic (TD) as the initial agent of choice for most persons with uncomplicated hypertension (TD strategy). 1 This is despite recognition that blood pressure (BP) response to any single antihypertensive drug is characterized by marked interindividual variation. 2,3 Causes of variation in response are incompletely understood but are hypothesized to reflect the heterogeneity of pathophysiologic mechanisms under lying hypertension as well as variation in the counterregula tory physiological responses to BP reduction. 4, 5 It is recognized that the reninangiotensin system (RAS) plays an important role in BP regulation and that hypertensives are characterized by interindividual variation in the activity of this system. 6, 7 Laragh and colleagues have long advocated initial drug selec tion based on an estimation of the activity of the RAS (plasma renin activity (PRA) strategy). 8, 9 Persons with low (suppressed) PRA are hypothesized to have sodium volume-dependent hypertension, directing initial therapy to a diuretic, whereas those with higher (nonsuppressed) PRA are hypothesized to have vasoconstrictiondependent hypertension mediated by angiotensin II, directing initial therapy to drugs that directly block renin release or the formation or action of angiotensin II (RAS blockers). 9 The clinical usefulness of this approach has been ques tioned. 7 Moreover, a PRA strategy of predicting drug response in a large sample of men with diastolic hyperten sion was shown to be no more effective than a method based on age and race, two more easily determined characteristics that are correlated with PRA. 10 In this strategy, older age and black race are used as markers for low PRA, whereas younger age and white race are markers for higher PRA (age/ race strategy). 11 Which of the 3 competing strategies (TD, 
Current treatment guidelines in the United States suggest a thiazide diuretic (TD) as the initial agent of choice for most persons with uncomplicated hypertension (TD strategy). 1 This is despite recognition that blood pressure (BP) response to any single antihypertensive drug is characterized by marked interindividual variation. 2, 3 Causes of variation in response are incompletely understood but are hypothesized to reflect the heterogeneity of pathophysiologic mechanisms under lying hypertension as well as variation in the counterregula tory physiological responses to BP reduction. 4, 5 It is recognized that the reninangiotensin system (RAS) plays an important role in BP regulation and that hypertensives are characterized by interindividual variation in the activity of this system. 6, 7 Laragh and colleagues have long advocated initial drug selec tion based on an estimation of the activity of the RAS (plasma renin activity (PRA) strategy). 8, 9 Persons with low (suppressed) PRA are hypothesized to have sodium volume-dependent hypertension, directing initial therapy to a diuretic, whereas those with higher (nonsuppressed) PRA are hypothesized to have vasoconstrictiondependent hypertension mediated by angiotensin II, directing initial therapy to drugs that directly block renin release or the formation or action of angiotensin II (RAS blockers). 9 The clinical usefulness of this approach has been ques tioned. 7 Moreover, a PRA strategy of predicting drug response in a large sample of men with diastolic hyperten sion was shown to be no more effective than a method based on age and race, two more easily determined characteristics that are correlated with PRA. 10 In this strategy, older age and black race are used as markers for low PRA, whereas younger age and white race are markers for higher PRA (age/ race strategy). 11 Which of the 3 competing strategies (TD, age/race, PRA) leads to the highest rate of control is uncer tain. To address this question we took advantage of BP response information from 2 large studies in biracial samples of adults with uncomplicated essential hypertension treated with a TD or an angiotensin receptor blocker to determine BP control rates for each of the 3 drug selection strategies.
Methods study population
This study represents a retrospective analysis of data pre viously collected in the Genetic Epidemiology of Responses to Antihypertensives (GERA) study. 12, 13 The GERA study was designed to determine the role of genetic variation in explaining interindividual differences in response to a TD in 286 black subjects and 284 white subjects (protocol 1) and to an angiotensin II receptor blocker in 248 black subjects and 278 white subjects (protocol 2). Independent patient sam ples were recruited for each protocol.
Study procedures for GERA have been previously described. 12, 13 Briefly, healthy men and women aged 30-59 years with essential hypertension were recruited at Emory University in Atlanta, Georgia (black subjects), and the Mayo Clinic in Rochester, Minnesota (white subjects). The study protocol was approved by the institutional review boards of both institutions. All subjects provided written informed consent. In Atlanta, black subjects were recruited through outpatient medical clinics at Grady Memorial Hospital, the Hypertension and Renal Diseases Research Center at Emory University, advertisements in public media, and mailing lists of registered voters. In Rochester, white subjects were recruited from a list of all residents of Olmsted County with the diagnosis of essential hyperten sion who had been seen by a healthcare provider within 3 years of recruitment. Essential hypertension was defined as a BP >140/90 mm Hg or a previous diagnosis of essential hypertension and current treatment with antihypertensive medication. Exclusions of participation included a known secondary cause of hypertension. Women using oral contra ceptive medications were disqualified; however, those receiv ing postmenopausal hormone replacement were allowed.
At enrollment, subjects were instructed by trained dieticians to maintain a standard sodium intake of 2 mmol/ kg/day throughout the study periods. Adherence was monitored weekly by 24hour urine collections alternating with recall diaries. Antihypertensive medications were discontinued, and subjects were evaluated every other week during a 4-6 week washout phase. Once stable elevation of BP (>90 mm Hg diastolic but <180/110 mm Hg) was achieved, antihypertensive therapy was administered for 4-6 weeks. Subjects were treated with 25 mg of hydrochlorothiazide (HCTZ) orally once daily for 4 weeks (protocol 1) or 16 mg of candesartan orally once daily for 2 weeks with a subsequent increase to 32 mg orally once daily for 4 additional weeks (protocol 2). BP was measured in triplicate 3 minutes apart in the seated position after 5 minutes of rest, as previously described. 12, 13 The average of the second and third readings was used for all analyses. BPs were measured at the end of the washout period and at the end of the treatment period.
All readings were made in the morning at the end of the dosing interval. Compliance with drug therapy was assessed by pill counts at each study visit.
laboratory analyses
At the end of the washout period, blood was drawn in the morning after 30 minutes in the seated position. PRA was determined by radioimmunoassay of angiotensin I in the presence of reagents that inhibit angiotensin I-converting enzyme and angiotensinases (Dupont Company, Boston MA, for protocol 1; DiaSorin, Stillwater MN, for protocol 2). PRA determinations by both assays were performed according to the manufacturers' recommendations. The standard incuba tion time for the Dupont assay is 1 hour, whereas the stand ard incubation time for the DiaSorin assay is 3 hours.
statistical analyses
Data were summarized by calculating means and SDs or medians and upper and lower quartiles for quantitative variables and percentages for categorical variables. P values for differences in quantitative variables were calculated using analysis of variance for variables that were normally distributed and the Mann-Whitney rank sum test for quan titative variables that were not normally distributed. In all analyses, statistical significance was inferred when P < 0.05. BP was considered controlled if it was <140 mm systolic and <90 mm Hg diastolic at the end of drug therapy. Control rates were calculated for the following 3 strategies: (i) HCTZ for all subjects (TD strategy); (ii) HCTZ for all black subjects and for white subjects aged ≥50 years, with candesartan for white subjects aged <50 years (age/race strategy); and (iii) HCTZ if PRA < 0.6 ng/ml/h (suppressed PRA) and cande sartan if PRA ≥ 0.6 ng/ml/h (nonsuppressed PRA) (PRA strategy). A formal test of the null hypothesis of equality of control rates between 2 strategies was based on the fact that each strategy involves a choice between 1 of 2 antihyperten sive drugs within each of 8 age/race/PRA strata. Within each of these 8 strata, the difference in control rates was calculated as the difference between 2 binomial proportions with asso ciated SEs. The overall difference in control rates between strategies is a weighted average of the 8 stratumspecific dif ferences in control rates. If both strategies dictated the same choice of drug in a given stratum, then the rate difference for that stratum was zero, and its SE was zero. For stratum weights, we used the number of subjects in the stratum as a proportion of the total sample. The usual formulae for bino mial proportions and linear combinations of independent random variables were used to derive a single z statistic to test the null hypothesis that the overall difference in control rates was zero, as well as to derive confidence intervals for the difference in control rates.
results sample description
The overall sample consisted of 534 (49%) black sub jects and 562 (51%) white subjects; 555 (51%) were women ( Table 1) . On average, subjects were obese (body mass index = 30.6 ± 5.3 kg/m 2 ) and had stage 1 hyper tension (147 ± 14/96 ± 5 mm Hg) after washout of previ ous therapy. In black subjects, BP response was greater to HCTZ than to candesartan (P < 0.001 for systolic BP and P = 0.005 for diastolic BP), and in white subjects, the reverse was true (P < 0.001 for both systolic BP and diastolic BP).
Within each age stratum, the proportion in each PRA stratum differed significantly by race (P < 0.001 for all com parisons) ( Table 2) . A majority of black subjects in each age stratum were in the suppressed PRA stratum (PRA < 0.6 ng/ ml/h) with no difference in the proportion within each PRA stratum across age strata (P = 0.95 for differences in the proportion within each PRA stratum across age strata). In contrast, the majority of white subjects in each age stratum were in the nonsuppressed PRA stratum (PRA ≥ 0.6 ng/ ml/h) with an increase in the proportion of suppressed PRA subjects in the aged ≥50 years stratum (P = 0.01 for differ ences in the proportion within each PRA stratum across age strata).
As expected in both racial subgroups, baseline systolic BP was higher in the aged ≥50 years strata than in the aged <50 years strata independent of PRA strata, whereas base line diastolic BP did not differ across the age/PRA strata (Supplementary Table S1 ).
control rate by treatment strategy
In the overall sample, the strategy of drug selection based on pretreatment PRA was associated with the highest con trol rate (69.4% with the PRA strategy vs. 61.3% with the age/race strategy (P < 0.001) and 53.8% with the TD strategy (P < 0.001)) ( Table 3) .
In black subjects, the strategy of drug selection based on pretreatment PRA was also associated with a higher control rate than drug selection based on the other 2 strategies, both of which directed the use of a TD for all subjects (control rate = 62.1% with the PRA strategy vs. 55.2% with the other 2 strategies; P = 0.02) ( Table 3 ). In black subjects with sup pressed PRA, the control rate was higher with HCTZ than with candesartan (57.9% vs. 36.9%; P < 0.001) ( Table 4) , whereas in black subjects with nonsuppressed PRA, the control rate was higher with candesartan than with HCTZ (70.5% vs. 52.7%; P = 0.02) ( Table 4) .
In white subjects, the strategy of drug selection based on pretreatment PRA was also associated with a higher control rate than drug selection based on either of the other 2 strate gies (control rate = 76.3% with the PRA strategy vs. 67.1% with the age/race strategy (P < 0.001) and 52.4% with the TD strategy (P < 0.001)) ( Table 3) . Consistent with the findings in black subjects, control rates were higher with candesartan than with HCTZ in white subjects with nonsuppressed PRA Unless otherwise noted, all values are expressed as mean (SD) except plasma renin activity (PRA) and 24-hour urine sodium, which are expressed as median (upper and lower quartiles). P values are for contrasts of hydrochlorothiazide (HCTZ) protocol vs. candesartan protocol. P values were calculated using analysis of variance or Mann-Whitney rank-sum test.
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure.
(89.6% vs. 53.8%; P < 0.001) (Table 4 ). However, in contrast with the findings in black subjects, control rates were also higher with candesartan than HCTZ in white subjects with suppressed PRA (63.7% vs. 49.2%; P = 0.006). Moreover, control rates in white subjects were also higher with cande sartan than with HCTZ in both age strata (aged <50 years: 77.2% vs. 49.7%, P < 0.001; aged ≥50 years: 78.7% vs. 55.9%, P < 0.001) ( Table 4) . Because of higher control rates with candesartan than with HCTZ in both PRA and age strata, an alternate "optional" strategy in white subjects of an RAS blocker for all was associated with the highest control rate of 78.1% (P < 0.06 compared with the PRA strategy).
effects of race, Pra, and age classification on differences in BP response to hctZ vs. candesartan
Differences in systolic and diastolic BP responses (mean, 95% confidence interval (CI)) with HCTZ vs. candesartan for each racial subgroup overall and by age/PRA strata within each racial subgroup are shown in Figure 1 . All values were adjusted for baseline BP, age, sex, and baseline urinary sodium excretion.
Overall in black subjects, compared with treatment with candesartan, treatment with HCTZ was associated with a greater decrease in mean systolic BP of −7 mm Hg (95% CI = −5 to −10 mm Hg; P < 0.001) and a greater decrease in mean diastolic BP of −2 mm Hg (95% CI = −1 to −4 mm Hg; P < 0.01). These differences in systolic and diastolic BP response favoring HCTZ did not differ across age strata but were greater in the suppressed PRA stratum. In the sup pressed PRA stratum, these greater differences in systolic and diastolic BP response favoring HCTZ also did not dif fer across age strata. In the nonsuppressed PRA stratum, there was no difference in SBP response between HCTZ and candesartan (P = 0.57). This was also true across age strata. However, compared with treatment with HCTZ, treatment Blood pressure control rate defined as percentage of subjects with BP < 140/90 mm Hg. Thiazide diuretic strategy was hydrochlorothiazide in all subjects. Age/race strategy was hydrochlorothiazide in all black subjects and in white subjects aged ≥50 years and candesartan in white subjects aged <50 years. Plasma renin activity (PRA) strategy was hydrochlorothiazide for pretreatment PRA < 0.6 ng/ml/h and candesartan for pretreatment PRA ≥ 0.6 ng/ml/h. *P < 0.001 vs. other strategies. **P = 0.02 vs. other strategies. with candesartan was associated with a greater decrease in mean diastolic BP of −3 mm Hg (95% CI = −1 to −6 mm Hg; P < 0.01) This difference in the mean diastolic BP responses favoring candesartan did not differ across age strata. Overall in white subjects, compared with treatment with HCTZ, treatment with candesartan was associated with a greater decrease in mean systolic BP of −5 mm Hg (95% CI = −3 to −7 mm Hg; P < 0.001) and a greater decrease in mean diastolic BP of −7 mm Hg (95% CI = −6 to −8 mm Hg; P < 0.001). These differences in mean systolic and diastolic BP response favoring candesartan decreased slightly across age strata and were greater in the nonsuppressed PRA stra tum. Within the nonsuppressed PRA stratum, these greater differences in systolic and diastolic BP response favoring candesartan were similar across age strata for systolic BP but were less in the aged ≥50 year age stratum for diastolic BP. In the suppressed PRA stratum, there was no difference in mean systolic BP response between HCTZ and candesartan (P = 0.57). This was also true across age strata. However, compared with treatment with HCTZ, treatment with can desartan was associated with a greater decrease in mean diastolic BP of −3 mm Hg (95% CI= −0.2 to −5 mm Hg; P = 0.03). This difference in diastolic BP response favoring candesartan did not differ across age strata.
differences in Pra values by method of determination
As noted in the Methods, PRA was determined using assays from Dupont for protocol 1 and from DiaSorin in protocol 2. PRA was determined in stored samples from 39 subjects using both assays (Supplementary Table S2 ). On average, PRA values were 0.44 ng/ml/h (32%; P < 0.001) lower with the DiaSorin assay than with the Dupont assay. This resulted in disagreement regarding PRA classification in 6 of 39 subjects (15%). All of these instances of disa greement involved patients with relatively low PRA values (≤1.13 ng/ml/h).
discussion
Of the 3 strategies recommended to select a diuretic (HCTZ) or an RAS blocker (candesartan) for initial treat ment of uncomplicated essential hypertension (TD, age/ race, PRA), the PRA strategy was associated with a higher BP control rate than either alternative strategy. This was true for the sample overall and for each racial subgroup. Whereas use of pretreatment PRA was the optimum strategy for drug selection in black subjects, selection of candesartan for all subjects regardless of age or pretreatment PRA was the opti mum strategy in white subjects.
Overall in black subjects, average BP response was greater to the TD than to the RAS blocking drug. This is consist ent with previous studies 14, 15 and is usually explained by the wellknown fact reaffirmed in our study that the majority of hypertensive black subjects have suppressed values of PRA. Also, consistent with previous studies, average BP response was greater in white subjects to the RASblocking drug than to the TD. 14 This observation is also usually explained by the higher prevalence of nonsuppressed values of PRA in white subjects. However, our data suggest that not all of the racial difference in response to candesartan vs. HCTZ can be explained by differences in PRA status. Although in white subjects the BP control rate was higher with cande sartan in the nonsuppressed PRA stratum than in the sup pressed PRA stratum, it was also significantly higher with candesartan than with HCTZ in both the suppressed and nonsuppressed PRA strata. In contrast, in black subjects a suppressed PRA was associated with a greater systolic and diastolic BP response to HCTZ than to candesartan, and a nonsuppressed PRA was associated with a greater diastolic BP response to candesartan. Although a nonsuppressed PRA was associated with a better systolic and diastolic BP response to candesartan than to HCTZ in white subjects, a suppressed PRA was also associated with a better diastolic BP response to candesartan (Figure 1) .What accounts for a higher BP control rate and a better BP response to can desartan than HCTZ in suppressed PRA white subjects is uncertain.
Laragh and colleagues were first to advocate measurement of PRA in all hypertensive patients to guide initial antihy pertensive drug selection. 8, 9 This recommendation has been controversial and not widely advocated by guideline groups. Moreover, a large study by the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents (VACSG) involving a biracial sample of 1,031 hyper tensive men randomized to 6 different monotherapies con cluded that the combination of age (younger or older than 60 years) and race (black or white) was equally predictive compared with PRA and preferable because it did not require additional laboratory measurements. 17 The results of our study demonstrated that in white subjects neither knowl edge of PRA status nor age provided additional information for drug selection, whereas in black subjects, knowledge of PRA status did provide additional information. Thus, our data would suggest that a drug selection strategy limited to using PRA alone or age/race criteria as a surrogate for PRA alone might be less effective for drug selection than one that uses a combination of these criteria.
However, our conclusions are limited to persons aged <60 years and may not apply to persons aged ≥60 years. Results of the VACSG study provide information about the effect of age on antihypertensive drug response that can be incorporated with our findings to speculate on a treat ment strategy that expands on the notion of combining the selective use of age, race, and PRA for optimum anti hypertensive drug selection rather than using PRA or age and race as a surrogate for PRAbased drug selection in all patient subgroups. In the VACSG study, the response rate in black subjects to HCTZ was higher in those aged ≥60 years than in those aged <60 years, whereas response to capto pril decreased across these age groups. [18] [19] [20] These observa tions would be consistent with an ageassociated increase in the proportion of black persons with suppressed PRA such that the value of measuring PRA in older black persons for drug selection might be questionable. Eighty percent of the black subjects in our study were classified as having sup pressed PRA. If this percentage increased significantly from this level in black hypertensive persons aged >60 years, measurement of PRA for drug selection would likely be cost ineffective because the number needed to measure to influence drug selection might be prohibitively high. The VACSG also observed that white subjects aged <60 years of age responded better to RAS blocking drugs than to HCTZ, consistent with our results. However, among white subjects aged ≥60 years of age, response rates to RAS blocking drugs and HCTZ were similar. This observation suggests the pos sibility that with aging in white persons, the advantage of an RAS blocker over HCTZ regardless of PRA status is dimin ished and, thus, measurement of PRA in older white per sons might be helpful in drug selection. The observations from the VACSG study taken together with the results of our study allows construction of a proposed strategy that com bines age/race criteria and PRA criteria for drug selection rather than using one as a surrogate for the other (Figure 2 ).
In this proposed strategy, white persons aged <60 years would preferentially be given an RAS blocker, whereas white persons aged ≥60 years would have drug selection based on PRA measurement. Drug selection in black persons aged <60 years would be guided by PRA, whereas black persons aged ≥60 years of age would preferentially be given a TD. Obviously, the effectiveness of such a strategy is unproven and would require confirmation in a future study.
This study has several limitations. This was not a single, prospective, clinical trial that exposed the same sample to both drug monotherapies. Response data from 2 separate studies, each with their own independently recruited sam ple, were retrospectively analyzed. Thus, the response to each drug in each racial subgroup in this analysis was inferred from the responses in a subset from each subgroup. The dose of HCTZ was fixed at 25 mg daily for 4 weeks, whereas the dose of candesartan was fixed at 32 mg for 4 weeks after 2 weeks of an interim dose of 16 mg daily. Theoretically the differences in dose and duration of therapy between HCTZ and candesartan could pose a bias in favor of candesar tan. However, it should be noted that the doses of drugs used in this analysis were chosen in the original protocols because they represent the maximum doses of each drug most commonly used as monotherapy for hypertension in clinical practice. Moreover, the additional decrease in mean BP from 2 weeks of candesartan 16 mg daily to 6 weeks of therapy (2 weeks of 16 mg daily and 4 weeks of 32 mg daily) was only −2.6/−1.6 mm Hg in the study sample. Thus, in our opinion, the differences in dose and duration of ther apy with the drugs used in this analysis are unlikely to be a significant source of bias regarding the inferences of this study. The assessment of the predictive value of age on drug response is limited by the fact that our sample consisted of individuals who were aged <60 years. Additionally, assess ment of BP control rates by selection strategy is limited to a relatively short period of observation. Longterm control with each drug was not assessed. It is also important to note that PRA measures were made under careful conditions that may not be easily reproduced in the usual clinical setting. Moreover, PRA measurements were made using 2 different assays, and an analysis suggests that up to 15% of partici pants would have been classified differently depending on the assay used. In all instances, the disagreements in PRA classification between the 2 assays involved participants with relatively low PRA. The lower values with the DiaSorin assay than with the Dupont assay likely resulted from the longer incubation time of the DiaSorin assay in samples with low renin. It is uncertain how these differences in PRA classi fication by assay might affect our results. However, we did repeat the analyses using a higher PRA cutpoint of 1.0 ng/ ml/h to distinguish suppressed from nonsuppressed PRA. The inferences of this study were unchanged, and with the higher PRA cutpoint, the percentage of subjects classi fied differently by the two assays was reduced from 15% to 5%. Lastly, whether the results of this study apply to RAS blocking drugs other than candesartan is uncertain. Thus, the results of this analysis should be considered exploratory and in need of confirmation.
In conclusion, the results of our study suggest that in persons aged <60 years with uncomplicated essential hypertension, choice of initial antihypertensive drug ther apy using a PRA strategy is associated with higher control rates than a strategy based on age/race criteria or a strategy of using a TD as the initial drug of choice for all. In black subjects, the optimal control rate was achieved when ini tial drug selection was based on PRA and in white subjects when an RAS blocker was used as the initial drug of choice in all. Consideration of our results with those of previous studies suggests that control rates in uncomplicated hyper tension with drug monotherapy could be enhanced by use of a drug selection strategy that combines criteria of age, race, and PRA rather than a strategy that uses age/race cri teria as a surrogate for PRA. The value of this suggested strategy needs to be tested in a prospective clinical trial. 
